Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasted to Post FY2025 Earnings of $0.02 Per Share

Esperion Therapeutics, Inc. (NASDAQ:ESPR) – Research analysts at Zacks Research dropped their FY2025 earnings estimates for shares of Esperion Therapeutics in a report issued on Monday, April 29th. Zacks Research analyst K. Das now anticipates that the biopharmaceutical company will post earnings per share of $0.02 for the year, down from their prior forecast of $0.05. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.68) per share.

A number of other equities analysts have also recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research report on Monday, March 25th. Needham & Company LLC reaffirmed a “buy” rating and set a $8.00 price objective on shares of Esperion Therapeutics in a research report on Wednesday, April 10th. Finally, Bank of America cut shares of Esperion Therapeutics from a “buy” rating to a “neutral” rating in a research report on Wednesday, January 3rd. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, Esperion Therapeutics has an average rating of “Hold” and an average price target of $9.33.

Esperion Therapeutics Price Performance

Shares of NASDAQ ESPR opened at $2.04 on Tuesday. The company has a 50 day simple moving average of $2.36 and a 200-day simple moving average of $2.02. The company has a market capitalization of $386.38 million, a P/E ratio of -0.96 and a beta of 0.84. Esperion Therapeutics has a 1 year low of $0.70 and a 1 year high of $3.40.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, February 27th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.53) by $0.03. The firm had revenue of $32.25 million for the quarter, compared to analyst estimates of $26.84 million. During the same quarter in the prior year, the business earned ($0.76) EPS.

Institutional Investors Weigh In On Esperion Therapeutics

Institutional investors have recently modified their holdings of the company. Herbst Group LLC purchased a new stake in shares of Esperion Therapeutics during the 1st quarter worth $28,000. Chicago Partners Investment Group LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter worth $29,000. Private Portfolio Partners LLC acquired a new stake in Esperion Therapeutics during the 4th quarter worth $30,000. Simplicity Solutions LLC acquired a new stake in Esperion Therapeutics during the 3rd quarter worth $30,000. Finally, Simplicity Wealth LLC acquired a new stake in Esperion Therapeutics during the 1st quarter worth $44,000. 47.39% of the stock is owned by hedge funds and other institutional investors.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.